This is a working overview of hGH fragment, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-09-11 and is reviewed periodically as new material appears.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Gas chromatography–vacuum ultraviolet spectroscopy (GC-VUV) is a universal detection technique for gas chromatography. VUV detection provides both qualitative and quantitative spectral information for most gas phase compounds. GC-VUV spectral data is three-dimensional (time, absorbance, wavelength) and specific to chemical structure. Nearly all compounds absorb in the vacuum ultraviolet region of the electromagnetic spectrum with the exception of carrier gases hydrogen, helium, and argon. The high energy, short wavelength VUV photons probe electronic transitions in almost all chemical bonds including ground state to excited state. The result is spectral "fingerprints" that are specific to individual compound structure and can be readily identified by the VUV library. Unique VUV spectra enable closely related compounds such as structural isomers to be clearly differentiated. VUV detectors complement mass spectrometry, which struggles with characterizing constitutional isomers and compounds with low mass quantitation ions. VUV spectra can also be used to deconvolve analyte co-elution, resulting in an accurate quantitative representation of individual analyte contribution to the original response. This characteristically lends itself to significantly reducing GC runtimes through flow rate-enhanced chromatographic compression. VUV spectroscopy follows the simple linear relationship between absorbance and concentration described by the Beer–Lambert Law, resulting in more accurate retention time-based identification.
==== Avoiding expense ==== The second process that Herodotus describes was used by middle-class people or people who "wish to avoid expense". In this method, an oil derived from cedar trees was injected with a syringe into the abdomen. A rectal plug prevented the oil from escaping. This oil probably had the dual purpose of liquefying the internal organs but also of disinfecting the abdominal cavity. (By liquefying the organs, the family avoided the expense of canopic jars and separate preservation.) The body was then placed in natron for seventy days. At the end of this time, the body was removed and the cedar oil, now containing the liquefied organs, was drained through the rectum. With the body dehydrated, it could be returned to the family. Herodotus does not describe the process of burial of such mummies, but they were perhaps placed in a shaft tomb. Poorer people used coffins fashioned from terracotta.
== Immunogenicity == When insulin was originally purified from bovine or porcine pancreata, all the proinsulin was not fully removed. When some people used these insulins, the proinsulin may have caused the body to react with a rash, to resist the insulin, or even to make dents or lumps in the skin at the place where the insulin was injected. This can be described as an iatrogenic injury due to slight differences between the proinsulin of different species. Since the late 1970s, when highly purified porcine insulin was introduced, and the level of insulin purity reached 99%, this ceased to be a significant clinical issue. With respect to their influence on insulin pharmacokinetics, moderate concentrations of certain insulin antibodies may be of positive advantage to all diabetics without endogenous insulin secretion (e.g. people with type 1 diabetes) because insulin binding antibodies effectively increase the insulin's clearance rate and distribution space and help to prolong its pharmacological and biological half lives.
Sources: en.wikipedia.org
== Function == CGRP is produced in both peripheral and central neurons. It is a potent peptide vasodilator and can function in the transmission of nociception. In the spinal cord, the function and expression of CGRP may differ depending on the location of synthesis. CGRP is derived mainly from the cell bodies of motor neurons when synthesized in the ventral horn of the spinal cord and may contribute to the regeneration of nervous tissue after injury. Conversely, CGRP is derived from dorsal root ganglion when synthesized in the dorsal horn of the spinal cord and may be linked to the transmission of pain. In the trigeminal vascular system, the cell bodies of the trigeminal ganglion are the main source of CGRP. CGRP is thought to play a role in cardiovascular homeostasis and nociception. In the heart, CGRP acts as a chronotrope by increasing heart rate. Apart from these attributes, CGRP is known to modulate the autonomic nervous system and plays a role in ingestion. CGRP has moderate effects on calcium homeostasis compared to its extensive actions in other areas, such as the autonomic nervous system.
Naltrexone and its active metabolite 6β-naltrexol are competitive antagonists of the opioid receptors. Naltrexone is specifically an antagonist preferentially of the μ-opioid receptor (MOR), to a lesser extent of the κ-opioid receptor (KOR), and to a much lesser extent of the δ-opioid receptor (DOR). However, naltrexone is not actually a silent antagonist of these receptors but instead acts as a weak partial agonist, with Emax values of 14 to 29% at the MOR, 16 to 39% at the KOR, and 14 to 25% at the DOR in different studies. In accordance with its partial agonism, although naltrexone is described as a pure opioid receptor antagonist, it has shown some evidence of weak opioid effects in clinical and preclinical studies. By itself, naltrexone acts as an antagonist or weak partial agonist of the opioid receptors. In combination with agonists of the MOR such as morphine however, naltrexone appears to become an inverse agonist of the MOR. Conversely, the naltrexone remains a neutral antagonist (or weak partial agonist) of the KOR and DOR. In contrast to naltrexone, 6β-naltrexol is purely a neutral antagonist of the opioid receptors. The MOR inverse agonism of naltrexone, when it is co-present with MOR agonists, may in part underlie its ability to precipitate withdrawal in opioid-dependent individuals. This may be due to suppression of basal MOR signaling via inverse agonism. Occupancy of the opioid receptors in the brain by naltrexone has been studied using positron emission tomography (PET).
The first presidential debate was held on June 27, 2024, between Biden and Trump. Biden's performance was widely criticized, with commentators saying he frequently lost his train of thought and gave meandering answers. Several newspaper columnists declared Trump the winner, and polling indicated the majority of viewers believed Trump won. After the debate raised questions about his health and age, Biden faced calls to withdraw from the race, including from Democrats and the editorial boards of various major news outlets. Biden initially insisted that he would remain a candidate, but on July 21, he withdrew from the race, writing that this was "in the best interest of my party and the country". He immediately endorsed Harris to replace him as the party's presidential nominee. On August 6, 2024, Harris officially became the Democratic presidential nominee. This was the first time an eligible incumbent had withdrawn a bid for reelection since 1968. In the general election, Trump defeated Harris. The Senate went Republican for the first time since 2018. In a nationally televised speech after the election, Biden congratulated Trump and promised a "peaceful and orderly" transition of power. In a January 2025 interview, Biden claimed he could have defeated Trump had he not been persuaded to withdraw from the election, despite lagging behind Trump in polling. A YouGov poll conducted on November 6–7, 2024, found that if Biden had been the Democratic nominee, Trump would have won the popular vote by 49% to 42%. Trump won the popular vote over Harris by 49.8% to 48.3%.
== Post-scandal changes == The European Commission did not have a standardised set of rules to cover gifts, travel, and hospitality offered by third parties. President von der Leyen supported such a set of rules in 2019; however, it was not proposed until June 2023 to create an ethics body to create and manage common rules of conduct. The European Parliament's Special Committee on foreign interference and disinformation, and on strengthening integrity in the EP (ING2) adopted a set of recommendations to improve scrutiny, detection and sanction of such interference. The European Parliament revised its rules of procedure and its code of conduct in September 2023, placing six main obligations on MEPs:
Sources: en.wikipedia.org
=== Obesity and metabolic disorders === Microbial therapeutics are also being explored as treatments for obesity and metabolic diseases such as diabetes. Certain gut microorganisms influence how the body absorbs nutrients, stores energy, and regulates blood sugar. By changing the activity or composition of these microbes, it may be possible to improve metabolic health. In addition, genetically engineered bacterial and yeast have been developed to produce hormones that help regulate appetite and glucose levels. For example, some engineered microbes release substances similar to the hormone glucagon-like peptide-1 (GLP-1), which supports insulin release and promotes feelings of fullness. Because these microbes can live in the gut, they may provide longer-lasting effects than traditional medications.
Staining a cell with a dye such as Giemsa stain or crystal violet allows a microscopist to describe its size, shape, internal and external components and its associations with other cells. The response of bacteria to different staining procedures is used in the taxonomic classification of microbes as well. Two methods, the Gram stain and the acid-fast stain, are the standard approaches used to classify bacteria and to diagnosis of disease. The Gram stain identifies the bacterial groups Bacillota and Actinomycetota, both of which contain many significant human pathogens. The acid-fast staining procedure identifies the Actinomycetota genera Mycobacterium and Nocardia.
==== Groups and labels ==== AAA (band), Triple A, or Attack All Around, a Japanese pop band The AAA Girls or The American Apparel Ad Girls, a drag queen trio Against All Authority (-AAA-), an American ska-punk band Acid Angel from Asia (AAA), the first sub-unit of K-pop girl group TripleS American Accordionists' Association
=== Incompressible isotropic case === For an incompressible and isotropic Newtonian fluid in laminar flow only in the direction x (i.e. where viscosity is isotropic in the fluid), the shear stress is related to the strain rate by the simple constitutive equation
C-type natriuretic peptide (CNP), the third hormone, was isolated from the swine brain and could relax smooth muscle. The three hormones share a similar structural makeup but come from different genes. These preliminary findings produced more investigation to establish the genetic makeup and regulatory mechanisms of these molecules.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.